Drug Approval | January 03, 2024
Alembic Pharmaceuticals received 8 USFDA approvals in Q3FY24
The company has received five final approvals
The company has received five final approvals
Sirius JV will be owned 51% by Sirius and 49% by Adani
Marks remarkable acceleration in innovation using AI technology
Karkinos Healthcare has demonstrated exceptional dedication to privacy, setting a commendable example for businesses navigating the complexities of the digital landscape
NEIAFMR to be developed as the national hub for folk medicine
The product is expected to be launched in December 2023
Softovac Liquifibre expands the Softovac product portfolio and provides a choice for consumers who prefer time-tested Ayurvedic ingredients
V116 is an investigational, 21-valent pneumococcal conjugate vaccine specifically designed to protect adults
The launch of R3SET Detox Candies positions the brand at the forefront of the wellness journey
Trastuzumab deruxtecan (Enhertu) is indicated for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer
Subscribe To Our Newsletter & Stay Updated
